Press Room

2007 Press Releases

TSX:V - IXS
NASD OTC:BB: IXSBF

June 12, 2007

Dr. Ellen S. Vitetta joins InNexus Biotechnology Scientific Advisory Board

British COLUMBIA, Canada -- InNexus Biotechnology Inc. (TSX VENTURE: IXS) (OTCBB: IXSBF), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that Ellen S. Vitetta, Ph.D., Professor of Microbiology and Director of the Cancer Immunobiology Center at UT Southwestern Medical Center, Dallas, TX has joined InNexus’ newly formed Scientific Advisory Board. She joins Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation and InNexus SAB Chairman, Dr. Thomas Kindt, Dr. John D. Minna and Dr. Carlos L. Arteaga.

Welcoming Dr. Vitetta, Jeff Morhet, President & Chief Executive Officer of InNexus, said, “I’m honored and excited to have Ellen join our Scientific Advisory Board. She has endeavored to develop medicines from the bench to the patient and today stands atop her field. Our team and science will benefit from having her on the InNexus team."

In addition to Dr. Vitetta’s current positions as Professor of Microbiology and Director of the Cancer Immunobiology Center, she is holder of the Sheryle Simmons Patigian Distinguished Chair in Cancer Immunobiology and a Distinguished Teaching Professor. As an immunologist who does translational (“bench to bedside”) research, she has published 475 papers, edited several books, and is a co-inventor on 13 issued patents. Over the past two decades Dr. Vitetta has developed antibody-based “biological missiles” (immunotoxins) to destroy cancer cells and cells infected with HIV. These novel therapeutics have been evaluated in tissue culture, in animals and, since 1988, in >300 humans. She is the PI on 10 FDA INDs for Phase I and II clinical trials. In 2001, Dr. Vitetta’s group developed a recombinant protein vaccine against ricin which completed testing in human volunteers in 2005. The vaccine was safe and elicited neutralizing antibodies.

Dr. Vitetta is a member of Alpha Omega Alpha, the National Academy of Sciences, the American Academy of Science, the Institute of Medicine, the American Academy of Microbiology and the American Academy of Cancer Immunology. She is among the 100 most cited biomedical scientists and the 10 most cited women of the past several decades. She has been the recipient of the Pierce Immunotoxin Award, an NIH Merit Award, 16 Faculty Teaching Awards, the FASEB Excellence in Science Award, the American Society of Microbiology Abbott Clinical Immunology Award and the American Association of Cancer Research Rosenthal Prize. Dr. Vitetta was the 1993-94 President of the American Association of Immunologists and in 2002 was awarded its Mentoring Prize. In 2005, she became a founding member of UT Southwestern’s newly established Southwestern Academy of Teachers and was elected to the UT-system wide Academy of Health Science Education, 2006. In 2006, Dr. Vitetta was inducted into the Texas Women’s Hall of Fame by Governor Rick Perry. In 2007 the American Association of Immunologists awarded her its highest honor, the Lifetime Achievement Award.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of The Mayo Clinic and has its own in–house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward–looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

Contact:

Jeff Morhet
President & Chief Executive Officer
InNexus Biotechnology Inc.
jmorhet@ixsbio.com
480-862-7500